<< Read Full Article
<< Read Full Article
Second-Half Biotech: Healing the Wounded
- Loading Comments...
The biotech sector, a furnace of stock-market Darwinism, could be a setting for rebirth in the second half of 2005.
Biogen Idec(BIIB Quote) and Chiron(CHIR Quote) will both be searching for redemption after high-profile disasters. Meanwhile, Amgen(AMGN Quote) hopes to surprise Wall Street with strong earnings and report positive results for drugs that are crucial to its future pipeline.
The highest drama involves Biogen, whose withdrawal of multiple sclerosis drug Tysabri in February lopped 40% off the company's market capitalization and raised survival concerns for its smaller partner, Elan(ELN Quote). ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |


Connect with TheStreet